DermTech, Inc. provided revenue guidance for the full year 2022. For the period, the company expects assay revenue to be between $16 million and $19 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.303 USD | -3.93% | -13.43% | -82.69% |
14/05 | DermTech, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
14/05 | Earnings Flash (DMTK) DERMTECH Posts Q1 Revenue $3.8M | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-82.69% | 1.09Cr | |
-4.22% | 1.24TCr | |
-0.60% | 821.51Cr | |
+6.61% | 571.74Cr | |
-10.21% | 411.13Cr | |
-60.35% | 268.39Cr | |
+10.62% | 267.87Cr | |
-5.50% | 237.39Cr | |
+16.77% | 206Cr | |
-9.18% | 180.32Cr |
- Stock Market
- Equities
- DMTK Stock
- News DermTech, Inc.
- Dermtech, Inc. Provides Revenue Guidance for the Full Year 2022